LGND News and Press, Ligand Pharmaceuticals Incorporated From 05/02/21

[[ADUS]], [[AGR]], [[AWK]], [[AWR]], [[BLDP]], [[BRX]], [[BWXT]], [[CAR]], [[CBT]], [[CC]], [[CHGG]], [[CR]], [[EVER]], [[FANG]], [[FLS]], [[FN]], [[FRPT]], [[HLIT]], [[IAG]], [[IRBT]], [[JKHY]], [[KFRC]], [[KMT]], [[LEG]], [[LGND]], [[LTHM]], [[MAXR]], [[MOS]], [[MWA]], [[MYGN]], [[NSP]], [[...

Ligand Pharmaceuticals (NASDAQ:LGND) is scheduled to announce Q1 earnings results on Monday, May 3rd, after market close.The consensus EPS Estimate is $1.13 (+27.0% Y/Y) and the consensus Revenue Estimate is $63M (+90.0% Y/Y).Over the last 2 years, LGND has beaten EPS estimates 100% of the ti...

Top-rated stocks in our research that also have a strong track record of beating analyst expectations. Stock ideas cutting across most sectors. Over 50 ideas worth considering for watch lists. For further details see: Stocks With The Best History Of Beating Estimates

The Boyar Value Fund seeks long-term capital appreciation, which it pursues by investing primarily in equity securities of companies that are believed by the Fund's investment adviser to be intrinsically undervalued. Toward the end of the quarter, we saw one of the largest financial i...

Ligand Pharmaceuticals' (LGND) CyDex Unit and Lupin have settled a patent lawsuit over CyDex's cancer drug Evomela.Lupin won't sell a generic version of the drug until a date agreed upon by the two companies.Evomela is used in the treatment of multiple myeloma.Ligand receives a 20% royalty fr...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report financial results for the three months ended March 31, 2021 after the close of the U.S. financial markets on Monday, May 3, 2021 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers...

The market seemed to defy logic in late January, when the WallStreetBets subreddit became a platform for organizing retail investors against short-sellers. In the frenzy of actions that followed, a number of companies that seemed long past their primes saw their share prices spike temporari...

Unlike traditional biotech companies, Ligand’s business model revolves around helping biotech companies to discover and develop medicines. Scalable platform technologies such as Captisol, OmniAb, Ion Channel Technologies and Pelican Expression and a strong pipeline of partners ...

Investing in the biotech industry can be a long road to gains given the sector’s volatility. Even with a good understanding of the system, no one can predict which biotechnology treatment, device or therapy will give the biggest return, which makes biotechnology exchange-tr...

The following slide deck was published by Ligand Pharmaceuticals Incorporated in conjunction with this event. For further details see: Ligand Pharmaceuticals (LGND) Investor Presentation - Slideshow